Over 14 Million People in U.S. Cite Upper Arm Fat as Troubling
Company Announces Upcoming Launch of New CoolAdvantage™ Petite Applicator,
Designed to Optimize CoolSculpting Performance in Upper Arms
PLEASANTON, Calif., Jan. 26, 2017 (GLOBE NEWSWIRE) -- ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced that CoolSculpting® is FDA-cleared for upper arms, making it the only non-invasive fat removal technology cleared by the FDA to address this body area.
“There are 29 million people in the U.S. interested in CoolSculpting, with more than 14 million expressing concern about unwanted arm fat, making arms the third most popular area for consideration of non-invasive fat reduction,” said Mark Foley, President and Chief Executive Officer of ZELTIQ. "As demonstrated with our recent FDA clearance, we are committed to investing in R&D and clinical research to provide consumers with solutions that they desire most. CoolSculpting’s ability to successfully treat upper arm fat is a testament to our technology’s efficacy and versatility, as well as our position as the market leader in non-invasive fat reduction.”
The company also announced that it will be launching the CoolAdvantage Petite applicator for the CoolSculpting system in order to optimize the performance of CoolSculpting in the upper arms, with full commercial release targeted for the middle part of the year. The newest member of the CoolAdvantage family of applicators, the CoolAdvantage Petite treatment comes with two interchangeable contours designed to uniquely treat the upper arm area in just 35 minutes.
"My patients have been asking for a non-invasive solution for their unwanted arm fat so I am thrilled to be able to offer them a proven solution that is safe and effective," said Grant Stevens, MD, FACS, Founder and Medical Director of Marina Plastic Surgery and Medical Director of Body by OrangeTwist. "We anticipate a lot of interest from our patients now that there is an FDA-cleared solution to treat this challenging area."
CoolSculpting is a safe and effective treatment for non-invasive fat reduction with unmatched clinical evidence. With more than 70 peer-reviewed clinical papers and abstracts and over 3.5 million treatments performed to date in over 80 countries around the world, CoolSculpting is the clear market leader in non-invasive fat reduction. CoolSculpting is FDA-cleared for the treatment of fat bulges in the submental area, thigh, abdomen, flank, bra and back fat area, underneath the buttocks and now, the upper arm.
CoolSculpting is available through an elite network of CoolSculpting Centers worldwide. Dermatologists, plastic surgeons and leading aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.com.
About the CoolSculpting® Procedure
CoolSculpting is a non-surgical, clinically proven procedure that selectively reduces unwanted fat using a patented cooling technology. Cleared by the FDA, CoolSculpting works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without affecting surrounding tissue, and the treated fat cells are gone for good. Millions of CoolSculpting treatments have been performed by more than 5,700 CoolSculpting systems in over 80 countries. Market research indicates up to a 95 percent customer satisfaction rate with the CoolSculpting procedure. CoolSculpting is available through an elite network of CoolSculpting Centers worldwide. Dermatologists, plastic surgeons and leading aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.com.
About ZELTIQ® Aesthetics, Inc.
ZELTIQ. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.
The statements made in this press release regarding ZELTIQ's targeted mid-2017 full commercial release of the CoolAdvantage Petite applicator, and other statements relating to future expectations or events are forward-looking statements. The words “target,” "anticipate," "expect," "estimate," "planned," and similar words that denote future events or results identify these forward-looking statements. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond ZELTIQ's control and that could materially affect ZELTIQ's actual business operations. Factors that could materially affect ZELTIQ's business operations include, but are not limited to slower than expected product development as well as those other risks and uncertainties set forth in ZELTIQ's Quarterly Report on Form 10-Q for the third quarter ended September 30, 2016, filed with the SEC on November 9, 2016. These forward-looking statements speak only as of the date of this press release. ZELTIQ expressly disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events or otherwise.
MEDIA CONTACT: Jill Knepper Ketchum for ZELTIQ 310-437-2517 INVESTOR RELATIONS: Taylor Harris ZELTIQ, Senior Vice President and CFO 925-474-2500 Nick Laudico The Ruth Group for ZELTIQ 646-536-7030
Source:ZELTIQ Aesthetics, Inc.